BioVaxys Technology Corp. Closes Private Placement Successfully
BioVaxys Technology Corp. (CSE: BIOV) has announced the significant milestone of closing its previously announced non-brokered private placement. This move comes as part of the company’s strategy to enhance its capital structure and support its ongoing development in the biopharmaceutical sector.
Details of the Private Placement
The successful placement involved issuing a total of 24,812,340 Units, which raised approximately $1,240,617. Each unit consists of one common share and one whole common share purchase warrant. The warrants allow the holder to purchase additional common shares at a price of $0.15 for a period of 24 months from the date of issuance.
Changes to the Offering Size
Initially announced to raise up to $500,000 with 10 million units, the Private Placement was upsized multiple times to ultimately accommodate up to $1,500,000 with 30 million units. This adjustment reflects the strong interest from investors and the confidence in BioVaxys’ growth trajectory.
Distribution of Finder's Fees
Finder’s fees were also a component of this successful placement, amounting to a total of $4,800 cash along with 96,000 finder’s warrants, which share the same terms as the units issued. This strategy is crucial for incentivizing brokers to participate in the placement.
Proposed Units for Future Funding
In addition to the Private Placement, the Company announced its intention to issue 1,196,908 Proposed Units, priced at $0.03 each. These units are expected to address an inadvertent issuance of too few units to certain subscribers due to a currency conversion error in a previous offering. Each Proposed Unit will also consist of one common share and one whole common share purchase warrant, further demonstrating BioVaxys’ commitment to its investors.
Regulatory Compliance and Future Outlook
All Proposed Units issued will be subject to a four-month statutory hold period, in alignment with applicable securities laws. The issuing of these units is also subject to approval from the Canadian Securities Exchange, ensuring that BioVaxys remains compliant with regulatory standards. This level of diligence speaks to the Company’s dedication to upholding best practices in the market.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to making an impactful difference in patient lives through innovative immunotherapies. The company operates on groundbreaking technologies including the DPX™ platform and the HapTenix© tumor cell construct, targeting treatment for cancers and infectious diseases. BioVaxys has positioned itself as a forward-thinking leader in the biopharmaceutical field, with operations highlighted on the Canadian Securities Exchange under the ticker BIOV and listed on the Frankfurt Bourse as FRA: 5LB.
Frequently Asked Questions
1. What was the total amount raised in the private placement?
The total amount raised was approximately $1,240,617 from the issuance of 24,812,340 Units.
2. How do the warrants work?
Each warrant allows the holder to purchase one additional common share at an exercise price of $0.15 for a period of 24 months.
3. What are Proposed Units?
Proposed Units consist of one common share and one common share purchase warrant, priced at $0.03 each, aimed at correcting a prior issuance error.
4. How will the raised funds be utilized?
The raised funds are expected to support ongoing research and development activities within BioVaxys Technology Corp.
5. Where can I find more information about BioVaxys?
More information about BioVaxys can be found on their official website at www.biovaxys.com, and they are active on social media platforms as well.
